Macroporous poly(vinyl alcohol) microspheres bearing phosphate groups as a new adsorbent for low-density lipoprotein apheresis
Authors:
- Hui XieHXHui Xie
- Lisha SunLSLisha Sun
- Lailiang OuLOLailiang Ou
- Lianyong WangLWLianyong Wang
- Yaoting YuYYYaoting Yu
- Deling KongDKDeling Kong
- 23 November 2009
- journal article
- Published by IOP Publishing in Biomedical Materials
- Vol. 4 (6) , 065007
Abstract
A new low-density lipoprotein (LDL) adsorbent with phosphate groups as the ligand was prepared in this study. Macroporous poly(vinyl acetate-co-triallyl isocyanurate) microspheres were prepared using a free-radical suspension polymerization method. A hydrolysis reaction in sodium hydroxide/methanol changed the materials into poly(vinyl alcohol) (PVA) microspheres. Further reaction with phosphorus oxychloride in anhydrous DMF led to the LDL adsorbent PVA-phosphate microspheres. The preparation conditions such as reaction time, temperature and the amount of phosphorus oxychloride were optimized. The adsorption of plasma lipoproteins was examined by in vitro adsorption assays. The influence of adsorption time, plasma volume and ionic strength on the adsorption capacity was investigated. The circulation adsorption showed that the pathogenic lipoproteins in the plasma such as total cholesterol (TC), LDL and triglyceride (TG) could be removed markedly, in which the removal percentages were 42.9%, 45.0% and 44.74%, respectively. However, the reduction of high-density lipoprotein (HDL) and other normal plasma components was very slight. For in vivo experiment, rabbits were fed with high-cholesterol food to develop a hyperlipidemia model and treated by extracorporeal blood perfusion using the PVA-phosphate columns. Eight hyperlipidemia rabbits were treated with the PVA-phosphate adsorbent, and the removal of TC, LDL and TG was 45.03 +/- 6.64%, 48.97 +/- 9.92% and 35.42 +/- 14.17%, respectively. The sterilization and storage tests showed that the adsorbent was chemically and functionally stable. It could be easily sterilized by a common method and stored for months without loss of adsorption capacity. Therefore, this new PVA-phosphate-based LDL adsorbent may have potential for application in LDL apheresis.Keywords
This publication has 35 references indexed in Scilit:
- Heparin-mediated extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular diseaseTransfusion and Apheresis Science, 2004
- From Membrane Differential Filtration to Lipidfiltration: Technological Progress in Low‐density Lipoprotein ApheresisTherapeutic Apheresis and Dialysis, 2003
- Extracorporal Low‐density Lipoprotein Elimination by ImmunoadsorptionTherapeutic Apheresis and Dialysis, 2003
- Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trialsBMJ, 2000
- Low-Density Lipoprotein Adsorption for Arteriosclerotic PatientsArtificial Organs, 1996
- Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter studyAtherosclerosis, 1992
- Ten-Year Mortality from Cardiovascular Disease in Relation to Cholesterol Level among Men with and without Preexisting Cardiovascular DiseaseNew England Journal of Medicine, 1990
- Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- PLASMA EXCHANGE IN THE MANAGEMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLÆMIAThe Lancet, 1975
- Serum Cholesterol, Lipoproteins, and the Risk of Coronary Heart DiseaseAnnals of Internal Medicine, 1971